SERPASIL-ESIDRIX #2
LOE ApproachingNDAORALTABLET
Approved
May 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPASIL-ESIDRIX #2 is an oral tablet combination product approved in 1959 by Novartis. The specific mechanism of action and indications are not publicly detailed in available data, but the brand name suggests a fixed-dose combination historically used in cardiovascular therapy. This is a legacy product approaching loss of exclusivity.
LOE Approaching
As a legacy product with LOE approaching and no linked job openings, commercial teams are likely minimal and focused on managed decline rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal minimal hiring and career progression on this product. Working on SERPASIL-ESIDRIX #2 would involve legacy product management, compliance, and relationship preservation rather than growth, innovation, or skill development.
Medical Science LiaisonBrand Manager
Worked on SERPASIL-ESIDRIX #2 at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.